论文部分内容阅读
[目的]探讨双歧三联活菌治疗重症肺炎继发腹泻的临床疗效及影响因素。[方法]812例重症肺炎患者为研究对象,筛选重症肺炎继发腹泻的相关因素;将筛选出300例继发腹泻患者分为2组,治疗组采用双歧三联活菌联合常规抗生素治疗,对照组采用常规抗生素治疗,治疗结束后评价临床疗效。[结果]患者的年龄、住院时间、病情轻重、住院时侵入性操作情况、微生态制剂应用情况、激素应用与重症肺炎继发腹泻有关,可能是其危险因素;治疗组总有效率为93.3%,显著高于对照组(P<0.05)。[结论]患者年龄大、住院时间长、病情严重、住院时侵入性操作、激素应用和不给予微生态制剂治疗可以增加重症肺炎患者继发腹泻的发生,双歧杆菌三联活菌联合常规抗生素可以防治重症肺炎继发腹泻的发生。
[Objective] To investigate the clinical efficacy and influential factors of bifidobacterium triple viable bacteria in the treatment of secondary diarrhea due to severe pneumonia. [Methods] 812 patients with severe pneumonia were selected as the research object to screen the related factors of secondary diarrhea in severe pneumonia. The 300 patients with secondary diarrhea were divided into two groups. The treatment group was treated with bifid triple live bacteria combined with conventional antibiotics. Group using conventional antibiotic treatment, evaluation of clinical efficacy after treatment. [Results] The patient’s age, length of hospital stay, severity of illness, invasive operation during hospitalization, application of probiotics, hormone application and secondary diarrhea associated with severe pneumonia may be the risk factors. The total effective rate in the treatment group was 93.3% , Significantly higher than the control group (P <0.05). [Conclusion] Patients with older age, long hospital stay, serious illness, invasive operation when hospitalized, hormone application and non-administration of probiotics can increase secondary diarrhea in patients with severe pneumonia. Bifidobacterium triple live bacteria combined with conventional antibiotics can Prevention and treatment of severe pneumonia secondary to diarrhea.